A new metric called the Glycaemia Risk Index (GRI) is proving more effective at capturing the full picture of blood sugar control in people with type 1 diabetes than the standard measures doctors have relied on for decades. In a randomized clinical trial called GOLD, researchers found that when adults with type 1 diabetes switched from finger-stick blood tests to continuous glucose monitors (CGMs), their GRI scores improved by 9.8 points on a 0-100 scale, with improvements in both dangerously low and high blood sugar episodes. For people managing type 1 diabetes, this matters because it means their doctors may soon have a better tool for understanding whether their treatment is actually working. The traditional measure, called A1C (or HbA1c), shows only an average blood sugar level over three months. It doesn't reveal whether someone is experiencing dangerous blood sugar swings, frequent low blood sugar episodes, or other patterns that affect daily life and long-term health. Why Is the Glycaemia Risk Index Better Than Standard Measures? The GRI was designed to address a fundamental problem with how doctors currently evaluate diabetes control. While A1C and time in range (TIR), a metric that shows what percentage of the day blood sugar stays in a healthy zone, are useful, they don't tell the whole story. The GRI weighs different types of blood sugar problems differently, placing greater emphasis on severe lows and highs because these carry the most clinical risk. In the GOLD trial, researchers studied 125 adults with type 1 diabetes who used multiple daily insulin injections. Participants alternated between using a continuous glucose monitor and traditional finger-stick testing for two 26-week periods. The results showed that GRI demonstrated greater responsiveness to treatment changes than time in range alone. In fact, 85.4% of participants either maintained or improved their GRI risk zone classification when they switched to continuous glucose monitoring. What makes this finding significant is that the GRI captures information that standard metrics miss. The metric incorporates time spent in very low blood sugar (below 54 mg/dL), low blood sugar (54-70 mg/dL), high blood sugar (180-250 mg/dL), and very high blood sugar (above 250 mg/dL) ranges. By weighting severe excursions more heavily, the GRI provides a more clinically relevant assessment of actual diabetes risk. How Can Continuous Glucose Monitors Help Improve Your Diabetes Management? - Real-Time Glucose Tracking: Continuous glucose monitors provide readings every few minutes, allowing you to see patterns in your blood sugar throughout the day and night, rather than just snapshots from finger-stick tests. - Better Treatment Decisions: With detailed glucose data, you and your doctor can make more informed adjustments to insulin doses and meal timing, leading to more stable blood sugar control. - Reduced Severe Lows and Highs: The GOLD trial showed that switching to CGM reduced both hypoglycemia (low blood sugar) risk by 1.8 points and hyperglycemia (high blood sugar) risk by 2.8 points on the GRI scale. - Improved Quality of Life: Previous analyses from the GOLD trial demonstrated that CGM use improved treatment satisfaction, confidence in managing low blood sugar, and overall well-being compared to traditional testing methods. The GOLD trial also revealed something unexpected about who benefits most from switching to CGM. Exploratory analyses suggested that personality traits influenced how much people improved. Those who described themselves as thorough experienced greater reductions in low blood sugar risk, while people who reported being easily distracted or lazy, or who had less formal carbohydrate counting training, saw smaller improvements overall. This finding suggests that continuous glucose monitors work best when paired with active engagement in diabetes management. The technology provides the data, but using that data effectively requires attention and follow-through. For people with type 1 diabetes who are motivated to use the information their CGM provides, the benefits can be substantial. What Does This Mean for the Future of Diabetes Care? The introduction of the GRI as a clinical tool could reshape how doctors evaluate whether diabetes treatments are working. Currently, many people with type 1 diabetes focus on their A1C number because that's what their doctor emphasizes. But A1C doesn't capture day-to-day variability or the severity of blood sugar swings. A person could have an "acceptable" A1C while still experiencing dangerous low blood sugar episodes multiple times per week. By adopting the GRI, clinicians gain a single, easy-to-understand number that reflects both the frequency and severity of blood sugar problems. This is particularly important because previous research from the GOLD trial showed that conventional metrics like A1C and standard CGM parameters had only limited associations with improvements in how people actually felt and functioned in daily life. The research team, led by Marcus Lind at Sahlgrenska Academy in Sweden, emphasized that the GRI's broader dynamic range and weighting of more pronounced glucose values makes it more sensitive to capturing meaningful improvements in diabetes management. As continuous glucose monitoring becomes more common in type 1 diabetes care, having a metric that better reflects clinical reality could lead to more personalized, effective treatment strategies. For the estimated 1.6 million Americans with type 1 diabetes, this shift toward more comprehensive glucose metrics represents a meaningful step forward. It means that future doctor visits may focus less on a single A1C number and more on a complete picture of blood sugar stability, reducing both the dangerous lows that can cause seizures or loss of consciousness and the chronic highs that damage blood vessels and nerves over time.
